Alzheimer's disease: etiologies, pathophysiology, cognitive reserve, and treatment opportunities - PubMed (original) (raw)
Review
. 1998 Jul;51(1 Suppl 1):S2-17; discussion S65-7.
doi: 10.1212/wnl.51.1_suppl_1.s2.
Affiliations
- PMID: 9674758
- DOI: 10.1212/wnl.51.1_suppl_1.s2
Review
Alzheimer's disease: etiologies, pathophysiology, cognitive reserve, and treatment opportunities
J L Cummings et al. Neurology. 1998 Jul.
Abstract
Alzheimer's disease (AD) can be diagnosed with a considerable degree of accuracy. In some centers, clinical diagnosis predicts the autopsy diagnosis with 90% certainty in series reported from academic centers. The characteristic histopathologic changes at autopsy include neurofibrillary tangles, neuritic plaques, neuronal loss, and amyloid angiopathy. Mutations on chromosomes 21, 14, and 1 cause familial AD. Risk factors for AD include advanced age, lower intelligence, small head size, and history of head trauma; female gender may confer additional risks. Susceptibility genes do not cause the disease by themselves but, in combination with other genes or epigenetic factors, modulate the age of onset and increase the probability of developing AD. Among several putative susceptibility genes (on chromosomes 19, 12, and 6), the role of apolipoprotein E (ApoE) on chromosome 19 has been repeatedly confirmed. Protective factors include ApoE-2 genotype, history of estrogen replacement therapy in postmenopausal women, higher educational level, and history of use of nonsteroidal anti-inflammatory agents. The most proximal brain events associated with the clinical expression of dementia are progressive neuronal dysfunction and loss of neurons in specific regions of the brain. Although the cascade of antecedent events leading to the final common path of neurodegeneration must be determined in greater detail, the accumulation of stable amyloid is increasingly widely accepted as a central pathogenetic event. All mutations known to cause AD increase the production of beta-amyloid peptide. This protein is derived from amyloid precursor protein and, when aggregated in a beta-pleated sheet configuration, is neurotoxic and forms the core of neuritic plaques. Nerve cell loss in selected nuclei leads to neurochemical deficiencies, and the combination of neuronal loss and neurotransmitter deficits leads to the appearance of the dementia syndrome. The destructive aspects include neurochemical deficits that disrupt cell-to-cell communications, abnormal synthesis and accumulation of cytoskeletal proteins (e.g., tau), loss of synapses, pruning of dendrites, damage through oxidative metabolism, and cell death. The concepts of cognitive reserve and symptom thresholds may explain the effects of education, intelligence, and brain size on the occurrence and timing of AD symptoms. Advances in understanding the pathogenetic cascade of events that characterize AD provide a framework for early detection and therapeutic interventions, including transmitter replacement therapies, antioxidants, anti-inflammatory agents, estrogens, nerve growth factor, and drugs that prevent amyloid formation in the brain.
Similar articles
- Alzheimer's disease.
De-Paula VJ, Radanovic M, Diniz BS, Forlenza OV. De-Paula VJ, et al. Subcell Biochem. 2012;65:329-52. doi: 10.1007/978-94-007-5416-4_14. Subcell Biochem. 2012. PMID: 23225010 Review. - Alzheimer's disease pathogenesis and therapeutic interventions.
Parihar MS, Hemnani T. Parihar MS, et al. J Clin Neurosci. 2004 Jun;11(5):456-67. doi: 10.1016/j.jocn.2003.12.007. J Clin Neurosci. 2004. PMID: 15177383 Review. - [Alzheimer's disease: new prospects in therapy and applied experimental models].
Kubis AM, Janusz M. Kubis AM, et al. Postepy Hig Med Dosw (Online). 2008 Aug 5;62:372-92. Postepy Hig Med Dosw (Online). 2008. PMID: 18688208 Review. Polish. - Molecular basis of Alzheimer's disease.
Gooch MD, Stennett DJ. Gooch MD, et al. Am J Health Syst Pharm. 1996 Jul 1;53(13):1545-57; quiz 1603-4. doi: 10.1093/ajhp/53.13.1545. Am J Health Syst Pharm. 1996. PMID: 8809275 Review. - Etiology and pathogenesis of Alzheimer's disease.
Farlow MR. Farlow MR. Am J Health Syst Pharm. 1998 Nov 1;55 Suppl 2:S5-10. doi: 10.1093/ajhp/55.suppl_2.S5. Am J Health Syst Pharm. 1998. PMID: 9809105 Review.
Cited by
- Validation of a functional human AD model with four AD therapeutics utilizing patterned ipsc-derived cortical neurons integrated with microelectrode arrays.
Caneus J, Autar K, Akanda N, Grillo M, Long CJ, Jackson M, Lindquist S, Guo X, Morgan D, Hickman JJ. Caneus J, et al. Sci Rep. 2024 Oct 22;14(1):24875. doi: 10.1038/s41598-024-73869-9. Sci Rep. 2024. PMID: 39438515 Free PMC article. - An insight into the concept of neuroinflammation and neurodegeneration in Alzheimer's disease: targeting molecular approach Nrf2, NF-κB, and CREB.
Bhardwaj S, Grewal AK, Singh S, Dhankar V, Jindal A. Bhardwaj S, et al. Inflammopharmacology. 2024 Oct;32(5):2943-2960. doi: 10.1007/s10787-024-01502-2. Epub 2024 Jun 29. Inflammopharmacology. 2024. PMID: 38951436 Review. - Traumatic brain injury alters the effects of class II invariant peptide (CLIP) antagonism on chronic meningeal CLIP + B cells, neuropathology, and neurobehavioral impairment in 5xFAD mice.
Iannucci J, Dominy R, Bandopadhyay S, Arthur EM, Noarbe B, Jullienne A, Krkasharyan M, Tobin RP, Pereverzev A, Beevers S, Venkatasamy L, Souza KA, Jupiter DC, Dabney A, Obenaus A, Newell-Rogers MK, Shapiro LA. Iannucci J, et al. J Neuroinflammation. 2024 Jun 27;21(1):165. doi: 10.1186/s12974-024-03146-z. J Neuroinflammation. 2024. PMID: 38937750 Free PMC article. - Validation of a functional human AD model with four AD therapeutics utilizing patterned iPSC-derived cortical neurons integrated with microelectrode arrays.
Caneus J, Autar K, Akanda N, Grillo M, Long C, Jackson M, Lindquist S, Guo X, Morgan D, Hickman JJ. Caneus J, et al. Res Sq [Preprint]. 2024 May 20:rs.3.rs-4313679. doi: 10.21203/rs.3.rs-4313679/v1. Res Sq. 2024. PMID: 38826367 Free PMC article. Updated. Preprint. - The Biochemistry Behind Cognitive Decline: Biomarkers of Alzheimer's Disease.
Grari O, Elmoujtahide D, Sebbar E, Choukri M. Grari O, et al. EJIFCC. 2023 Dec 21;34(4):276-283. eCollection 2023 Dec. EJIFCC. 2023. PMID: 38303754 Free PMC article. Review.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous